Prostate Cancer Grade Migration Documented
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
A study of 3090 patients with HIV seen at a tertiary care hospital from June 2019 to June 2020 revealed a 1.8% prevalence of advanced chronic kidney disease, an approximately 4-fold increase from 2008-2010.
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
Reduced prostate cancer screening after USPSTF guidance changes may have contributed to an increase in diagnoses of metastatic disease, according to investigators.
County characteristics explain 18.9% of the variation in ESKD mortality, investigators reported.
From March 23 to July 4, 2020, the number of men newly diagnosed with prostate cancer dropped 48.3% compared with the corresponding period in 2019, according to investigators.
As kidney function decreases, the risk for sudden cardiac death increases, independent of a history of coronary heart disease, hypertension, and diabetes, a study found.
The natural history of nonmetastatic castration-resistant prostate cancer (nmCRPC) can serve as a benchmark for advances in imaging and treatment, according to investigators.
Study finds worse outcomes among patients who have CKD but no kidney failure.
In a large study of men with newly diagnosed diabetes, exposure to metformin in the previous year was associated with an increased risk for a prostate cancer diagnosis, whereas exposure 2 to 7 years previously was associated with decreased risk.